Marina Biotech, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of oligonucleotide therapies based on RNA interference (RNAi) and RNA (mRNA) transcriptions. Its pipeline includes a clinical program in Familial Adenomatous Polyposis, which is a precancerous syndrome; and two preclinical programs in malignant ascites and bladder cancer. The company was formerly known as MDRNA, Inc. and changed its name to Marina Biotech, Inc. in July 2010. Marina Biotech, Inc. was founded in 1983 and is headquartered in Bothell, Washington.